Literature DB >> 21854823

Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.

Vesna Blazevic1, Suvi Lappalainen, Kirsi Nurminen, Leena Huhti, Timo Vesikari.   

Abstract

Noroviruses (NoVs) and rotaviruses (RVs) are the two most important viral causes of severe gastroenteritis in young children worldwide. Live oral RV vaccines are already part of routine childhood immunization in many countries, but may be associated with low risk of intussusception and other potential risks associated with live vaccines. NoV capsid-derived virus-like particles (VLPs) are in early phase clinical trials, but there is no vaccine available yet. We suggest that there is a need for non-live vaccines against both enteric pathogens. We have combined NoV GII-4 VLPs and human RV recombinant VP6 (rVP6) protein produced by recombinant baculovirus (BV) expression system in insect cells and used this combination vaccine to immunize BALB/c mice parenterally. Strong systemic cross-reactive and cross-blocking antibody responses towards NoV and RV were induced, and there was no interference of the immune response to either antigen given in combination. Rather, we observed an adjuvant effect of rVP6 on the NoV-specific homologous and heterologous immune responses to genotypes not included in a vaccine formulation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21854823     DOI: 10.1016/j.vaccine.2011.08.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

2.  Meeting report VLPNPV: Sessions 1 and 2: Plenary.

Authors:  Frank Sainsbury
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.

Authors:  Daniel E Velasquez; Baoming Jiang
Journal:  Hum Vaccin Immunother       Date:  2019-06-13       Impact factor: 3.452

Review 4.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 5.  Vaccine against norovirus.

Authors:  Ming Tan; Xi Jiang
Journal:  Hum Vaccin Immunother       Date:  2014-05-05       Impact factor: 3.452

Review 6.  Prospects and Challenges in the Development of a Norovirus Vaccine.

Authors:  Nicolas W Cortes-Penfield; Sasirekha Ramani; Mary K Estes; Robert L Atmar
Journal:  Clin Ther       Date:  2017-07-26       Impact factor: 3.393

7.  The potential economic value of a human norovirus vaccine for the United States.

Authors:  Sarah M Bartsch; Benjamin A Lopman; Aron J Hall; Umesh D Parashar; Bruce Y Lee
Journal:  Vaccine       Date:  2012-09-28       Impact factor: 3.641

Review 8.  Infection control for norovirus.

Authors:  L Barclay; G W Park; E Vega; A Hall; U Parashar; J Vinjé; B Lopman
Journal:  Clin Microbiol Infect       Date:  2014-07-16       Impact factor: 8.067

9.  Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Jianping Li; Shousun Szu; Yasutaka Hoshino
Journal:  Vaccine       Date:  2012-08-09       Impact factor: 3.641

Review 10.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.